Bristol Myers Squibb & Co. (BMY) and Johnson & Johnson (JNJ) announced Friday they're stopping the Phase 3 Librexia ACS trial after an independent review determined the heart drug milvexian probably wasn't going to work. It's another disappointment in what has been a rough year for Bristol Myers on the clinical trial front.

The trial was testing whether milvexian, when added to standard antiplatelet therapy, could help patients who recently experienced an acute coronary syndrome event. For context, acute coronary syndrome is medical speak for when blood flow to the heart muscle suddenly gets blocked—usually by a clot. This umbrella term covers heart attacks (myocardial infarction) and unstable angina, which shows up as sudden, severe chest pain that can happen even when you're resting.

What the Data Showed

The decision came after a preplanned interim analysis by the Independent Data Monitoring Committee, which basically looked at the data mid-trial and said "this isn't going where we hoped." The committee determined the trial was unlikely to meet its primary efficacy endpoint—the main measure of whether the drug actually works.

The good news, if there is any here, is that no new safety concerns popped up. The safety profile matched what researchers had seen in previous milvexian studies, so at least the drug wasn't causing unexpected problems.

But here's the thing: milvexian isn't completely dead yet. The broader Librexia clinical program includes two other Phase 3 trials that are continuing as planned. One is studying patients with atrial fibrillation, and the other is looking at secondary stroke prevention. The independent committee recommended both trials keep going, with topline data expected in 2026.

What Analysts Are Saying

William Blair weighed in with a measured take on what this means for those other trials. The firm pointed out that acute coronary syndrome and secondary stroke prevention are different treatment settings, but they stem from similar biology—basically the same process of blood clots forming in arteries.

Here's where it gets a bit concerning: both the failed ACS trial and the ongoing stroke prevention trial use the same dose of milvexian—25 mg twice daily. Because of that, William Blair views Friday's news as "a modest negative signal" for the stroke prevention study.

The atrial fibrillation indication might be in better shape, though. Analyst Matt Phipps noted that AF is a distinct condition and represents the largest market opportunity. Plus, that trial is testing a higher dose—100 mg twice daily—which means Friday's setback might not predict what happens there.

"We believe near-term focus will continue to be on the upcoming ADEPT-2 readout of Cobenfy in Alzheimer's disease psychosis, particularly given the difficult year for Bristol Myers with multiple late-stage trial setbacks," Phipps wrote.

A Tough Year for Bristol Myers

And he's not kidding about those setbacks. Bristol Myers has had a string of late-stage trial failures in 2024:

• The Phase 3 ODYSSEY-HCM trial of Camzyos for non-obstructive hypertrophic cardiomyopathy missed both of its dual primary endpoints.
• The Phase 3 INDEPENDENCE trial of Reblozyl with JAK inhibitor therapy for myelofibrosis-associated anemia didn't meet its primary endpoint.
• The Phase 3 RELATIVITY-098 trial of Opdualag for adjuvant treatment of completely resected stage III-IV melanoma failed to meet its primary endpoint of recurrence-free survival.

When you're a major pharmaceutical company, your pipeline is your future. Late-stage trial failures don't just hurt today's stock price—they create gaps in your revenue projections years down the line as older drugs lose patent protection.

Bristol Myers (BMY) shares dropped 3.59% to $46.88 on Friday following the announcement, which makes sense given investors are now tallying up how many potential blockbusters have stumbled this year. The market is clearly losing patience with the company's clinical execution, even as other parts of the business continue to perform well.